Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

DHSC issues supply notification for Stanek and Sastravi tablets

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for various strengths of Stanek and Sastravi (levodopa/carbidopa/entacapone) tablets.

Teva and Accord are the suppliers of Stanek tablets and Sastravi and the anticipated re-supply dates range between June and August 2020, DHSC has said.


Supplies of Stalevo tablets which are considered equivalent, continue to remain available.

A copy of this medicine supply notification has been sent to all pharmacy NHS email addresses.

DHSC has also issued a medicine supply notification for all formulations of Ranitidine.

Ranitidine 50mg/2ml injection is anticipated to be unavailable until further notice.

Ranitidine film-coated tablets, effervescent tablets and oral solution continue to remain out of stock.

All formulations of Ranitidine are affected due to on-going regulatory investigations into the presence of the contaminant, N-nitrosodimethylamine (NDMA), in samples of ranitidine active substance.